Drugs / Recombinant human activated coagulation factor VII
Recombinant human activated coagulation factor VII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05487976 | Apr 2022 → Apr 2023 | hemophilia A, hemophilia B | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human activated coagulation factor VII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05487976 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.” NCT05487976 ↗ |